These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 33011273)
1. APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice. Lee ES; Kim HM; Lee SH; Ha KB; Bae YS; Lee SJ; Moon SH; Lee EY; Lee JH; Chung CH Free Radic Biol Med; 2020 Dec; 161():92-101. PubMed ID: 33011273 [TBL] [Abstract][Full Text] [Related]
2. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Cha JJ; Min HS; Kim KT; Kim JE; Ghee JY; Kim HW; Lee JE; Han JY; Lee G; Ha HJ; Bae YS; Lee SR; Moon SH; Lee SC; Kim G; Kang YS; Cha DR Lab Invest; 2017 Apr; 97(4):419-431. PubMed ID: 28165467 [TBL] [Abstract][Full Text] [Related]
3. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. Holterman CE; Thibodeau JF; Towaij C; Gutsol A; Montezano AC; Parks RJ; Cooper ME; Touyz RM; Kennedy CR J Am Soc Nephrol; 2014 Apr; 25(4):784-97. PubMed ID: 24262797 [TBL] [Abstract][Full Text] [Related]
4. A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats. Dorotea D; Kwon G; Lee JH; Saunders E; Bae YS; Moon SH; Lee SJ; Cha DR; Ha H Pharmacology; 2018; 102(3-4):180-189. PubMed ID: 30099457 [TBL] [Abstract][Full Text] [Related]
5. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Gorin Y; Cavaglieri RC; Khazim K; Lee DY; Bruno F; Thakur S; Fanti P; Szyndralewiez C; Barnes JL; Block K; Abboud HE Am J Physiol Renal Physiol; 2015 Jun; 308(11):F1276-87. PubMed ID: 25656366 [TBL] [Abstract][Full Text] [Related]
14. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318 [TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase. Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641 [TBL] [Abstract][Full Text] [Related]
16. Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. Jha JC; Dai A; Garzarella J; Charlton A; Urner S; Østergaard JA; Okabe J; Holterman CE; Skene A; Power DA; Ekinci EI; Coughlan MT; Schmidt HHHW; Cooper ME; Touyz RM; Kennedy CR; Jandeleit-Dahm K Diabetes; 2022 Jun; 71(6):1282-1298. PubMed ID: 35275988 [TBL] [Abstract][Full Text] [Related]
17. Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Yu P; Han W; Villar VA; Yang Y; Lu Q; Lee H; Li F; Quinn MT; Gildea JJ; Felder RA; Jose PA Redox Biol; 2014; 2():570-9. PubMed ID: 24688893 [TBL] [Abstract][Full Text] [Related]